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Association of Vitamin D Status and Clinical Outcome in Dogs with
a Chronic Enteropathy
H. Titmarsh, A.G. Gow, S. Kilpatrick, J. Sinclair, T. Hill, E. Milne, A. Philbey, J. Berry, I. Handel, and
R.J. Mellanby
Background: Dogs with a chronic enteropathy (CE) have a lower vitamin D status, than do healthy dogs. Vitamin D sta-
tus has been associated with a negative clinical outcome in humans with inﬂammatory bowel disease.
Objectives: To examine the relationship between serum 25 hydroxyvitamin D (25(OH)D) concentrations at diagnosis and
clinical outcome in dogs with a CE.
Animals: Forty-one dogs diagnosed with CE admitted to the Royal Dick School of Veterinary Studies, Hospital for Small
Animals between 2007 and 2013.
Methods: Retrospective review. Serum 25(OH)D concentrations were compared between dogs which were alive at follow
up or had died because of non-CE-related reasons (survivors) and dogs which died or were euthanized due to their CE (non-
survivors). A binary logistic regression analysis was performed to determine signiﬁcant predictors of death in dogs with CE.
Results: Serum concentrations of 25(OH)D at the time a CE was diagnosed were signiﬁcantly lower in nonsurvivors
(n = 15) (median nonsurvivors 4.36 ng/mL, interquartile range 1.6–17.0 ng/mL), median survivors (n = 26) (24.9 ng/mL
interquartile range 15.63–39.45 ng/mL, P < .001). Serum 25(OH)D concentration was a signiﬁcant predictor of death in dogs
with CE (odds ratio 1.08 [95% CI 1.02–1.18)]).
Conclusions: Serum 25(OH)D concentrations at diagnosis are predictive of outcome in dogs with CE. The role of vitamin
D in the initiation and outcome of chronic enteropathies in dogs is deserving of further study.
Key words: 25 (OH)D; Prognostic; Inﬂammatory bowel disease.
Chronic enteropathies in dogs are a major cause ofmorbidity and mortality.1 A diagnosis of chronic
enteropathy (CE) is made in dogs which have a several
week history of gastrointestinal signs such as weight
loss, vomiting, and diarrhea, and the absence of an
underlying etiology based on diagnostic evaluation and
the presence of an inﬂammatory inﬁltrate within gas-
trointestinal biopsies.2 The pathogenesis of CE in dogs
is considered to be multifactorial and includes factors
such as abnormal mucosal immunity, disrupted epithe-
lial barrier function, altered intestinal microbial ﬂora,
environment, and genetics.2,3
Dogs with CE have lower serum concentrations of 25
hydroxyvitamin D (25(OH)D), which is the vitamin D
metabolite widely used to assess vitamin D status, than
do healthy dogs and hospitalized dogs with nongas-
trointestinal illnesses.4,5 In addition, the severity of the
clinical signs, as assessed by the canine inﬂammatory
bowel activity index (CIBDAI), correlates with serum
25(OH)D concentrations in dogs with a CE.5 However,
the prognostic signiﬁcance of serum 25(OH)D concen-
trations has not been investigated in dogs with a CE.
In contrast, the relationship between vitamin D status
and IBD has been extensively explored in human medi-
cine. In human patients with IBD, notably ulcerative
colitis and Crohn’s disease, vitamin D deﬁciency is a
frequent ﬁnding.6–9 Higher predicted vitamin D status
has been associated with a reduced risk of developing
Crohn’s disease.10 Among people with IBD, 25(OH)D
concentrations are related to disease severity scores and
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patient quality of life.11–13 Low plasma 25(OH)D con-
centrations have also been associated with an increased
risk of surgery and longer hospitalization periods in
patients with either Crohn’s disease or ulcerative colitis.14
In addition, normalization of 25(OH)D concentrations in
patients with Crohn’s disease has been associated with a
reduction in the risks associated with surgery.14 Vitamin
D status has also been linked to IBD treatment out-
comes, as low pretreatment vitamin D status has been
associated with reduced durability of response to antitu-
mor necrosis factor (TNF)-a treatment.15 Studies have
also demonstrated improvements in disease activity
scores and quality of life scores in Crohn’s disease
patients supplemented with oral vitamin D.16,17
The hypothesis of this study was that the vitamin D
status would not be diﬀerent in dogs that died or were
euthanized because of the complications associated with
their CE compared to dogs which were alive at follow
up or had died because of diseases unrelated to their
CE. The aim of this study was to measure serum con-
centrations of 25(OH)D, alongside a range of clinical
and biochemical variables, in dogs with a conﬁrmed
diagnosis of CE and known clinical outcome.
Material and Methods
Study Population
The records of dogs referred to the Hospital for Small Animals,
Royal Dick School of Veterinary Studies for investigation of
chronic gastrointestinal disease (more than 3 weeks in duration)
between 2007 and 2013 were retrospectively reviewed. Dogs were
considered eligible for inclusion in the study if they had presenting
clinical signs consistent with a CE, which included any of the fol-
lowing: vomiting, diarrhea, increased borborygmi, abdominal pain,
increased or decreased appetite, and weight loss. All dogs were
considered eligible if they had histopathological evidence of
inﬂammation within the small or large intestine and there were no
clinically relevant abnormalities detected on hematology, biochem-
istry, or abdominal ultrasonography, which were not attributable
to CE. In addition, a stored frozen serum sample from each dog,
collected at the time of diagnosis was required for retrospective
analysis of 25(OH)D concentrations. Hematology variables (total
white blood cell count, mature neutrophils, band neutrophils lym-
phocytes, monocytes, eosinophils, basophils, total red blood cell
counts, packed cell volume, hemoglobin, mean cell volume, mean
cell hemoglobin concentration, and platelet number) were mea-
sured on ADVIA(r) 2120i System with Autoslide.a Biochemistry
variables (albumin, alanine transaminase [ALT], alkaline phos-
phatase [ALP], bile acids, bilirubin, total calcium, creatinine, glob-
ulin, phosphate, potassium, sodium, chloride, urea, and glucose)
were measured on an ILab650 biochemistry analyzer.b Clinical
records were also reviewed for the results of fecal parasitology.
Canine inﬂammatory bowel disease activity index (CIBDAI) scores
were calculated as follows: appetite, activity levels, vomiting, fecal
consistency, fecal frequency, and weight loss were each scored
from 0 to 3. A score of 0 indicated no changes were present, a
score of one indicated mild changes, 2 moderate changes, and 3
severe changes. In addition, a score of one point was added if the
feces contained blood or mucus. The area of intestinal tract which
was biopsied (duodenum or duodenum and colon) was determined
based on the presenting clinical signs and was at the discretion of
the primary clinician managing the case. A diagnosis of CE was
made if there was histological evidence of intestinal inﬂammation
and no clear underlying cause.
Vitamin D Analysis
Serum samples retained for 25(OH)D measurement were fro-
zen after being used for routine biochemical analysis. They were
stored at 70°C before being sent to the laboratory for analysis
on dry ice. Serum 25(OH)D has been shown to be stable under
these conditions.18 Serum concentrations of 25(OH)D were mea-
sured as previously described in detail.19,20 Samples were
extracted using acetonitrile and applied to C18 Silica Sep-paks.
Separation of metabolites was by straight phase high perfor-
mance liquid chromatography (HPLC)c using a Hewlett-Packard
Zorbax-Sil Columnd eluted with hexane:propan-2-ol:methanol
(92 : 4 : 4). Serum 25(OH)D2 and 25(OH)D3 were measured
separately by application to a second Zorbax-Sil Column eluted
with hexane:propan-2-ol (98 : 2) and quantiﬁed by ultraviolet
absorbance at 265 nm and corrected for recovery (sensitivity
5 nmol/l, intra- and interassay coeﬃcients of variation 3.0 and
4.2%, respectively).21 Total 25(OH)D was deﬁned as the sum of
25(OH)D2 and 25(OH)D3. This laboratory is accredited by
CPA UK (CPA number 0865) and has been certiﬁed as proﬁcient
by the international Vitamin D Quality Assurance Scheme
(DEQAS).
Histopathology
Where available, the slides of the original duodenal biopsies
were reviewed by a single veterinary pathologist. A qualitative
scoring system (World Small Animal Veterinary Association
[WSAVA] Standards for the Diagnosis of Gastrointestinal Inﬂam-
mation in Endoscopic Biopsy Samples)22 was used to assess the
degree of inﬂammation. The template for this system assesses the
following histological changes (villous stunting, epithelial injury,
crypt distension, lacteal dilatation, and mucosal ﬁbrosis) and
inﬂammatory inﬁltrates (intraepithelial lymphocytes, lamina pro-
pria lymphocytes and plasma cells, lamina propria eosinophils,
and lamina propria neutrophils). The changes for each of the vari-
ables listed were graded as normal (0), mild (1), moderate (2), or
severe (3). The sums of all these variables were added together to
determine an intestine inﬂammatory score which ranged from 0
(normal) to 30 (very severe).
Outcome
For each dog enrolled, follow-up data was obtained by review-
ing clinical records and by telephone contact with referring
veterinary surgeons and owners. Outcome was recorded as sur-
vivors if the dogs were alive at follow up or had died because of
a non-CE-related illnesses or nonsurvivors if dogs had died or
were euthanized because of the complications associated with
CE.
Statistical Analysis
Univariable measures were compared between dogs which sur-
vived and nonsurviving dogs using a Mann–Whitney U-test. A
Fisher’s exact test was used to compare the sex of surviving and
nonsurviving dogs. A binary logistic regression model was used to
estimate the association between outcome (survivors versus non-
survivors) and serum 25(OH)D concentrations conditional on a
range of other candidate predictors. Stepwise selection of variables
was used to minimize Akaike Information Criteria (AIC), which is
a parameter-penalized measure of model ﬁt. Duodenal histology
scores were classiﬁed into 3 approximate tertiles (low <7, medium
7–8, high >8) for the regression model. The statistical analysis was
performed using R statistical system (R Development Core Team
2012).
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Ethical Review
Informed consent for the use of residual clinical blood samples
for research purposes was obtained at admission for each dog
enrolled. Ethical approval for the study was obtained from the
University of Edinburgh’s Veterinary Ethical Review Committee.
Results
Signalment
Forty-one dogs were included in the study. There
were 15 nonsurvivors and 26 survivors. In the nonsur-
vivors group, 2 dogs were intact males, 7 were neutered
males, 1 was an intact female, and 5 were neutered
females. In the survivors group, 7 dogs were intact
males, 11 were neutered males, and 8 were neutered
females. Breeds in the nonsurvivors groups included
Border Collie (n = 1), Boxer (n = 3), Cavalier King
Charles Spaniel (n = 1), Cross Breed (n = 3), German
Short Haired Pointer (n = 1), Hungarian Vizsla (n = 1),
Italian Greyhound (n = 1), Pyrenees Mountain Dog
(n = 1), Springer Spaniel (n = 1), Staﬀordshire Bull Ter-
rier (n = 1), and West Highland White Terrier (n = 1).
In the survivors group, breeds included Border Terrier
(n = 1), Boxer (n = 7), Cocker Spaniel (n = 1), Cavalier
King Charles Spaniel (n = 1), Chinese Crested (n = 1),
Cross Breed (n = 1), Irish Setter (n = 2), Labrador
Retriever (n = 2), Lurcher (n = 2), Rottweiler (n = 1),
Shar-pei (n = 1), Shetland Sheep Dog (n = 1), Springer
Spaniel (n = 1), Staﬀordshire Bull Terrier (n = 1), Toy
Poodle (n = 2), and Yorkshire Terrier (n = 1).
Clinical Findings
The median duration of clinical signs at diagnosis
was 3 months in the nonsurvivors (range 1–10 months)
and 3.5 months (range 0.75–24 months) in the survivors
group. Hematology, biochemistry, and abdominal ultra-
sonography ﬁndings did not reveal any clinically rele-
vant abnormalities in any of the 41 dogs which could
not be attributed to their CE. Fecal parasitology was
performed in 36 dogs and did not reveal evidence of
parasitic infection in any of the samples. Twelve dogs
underwent gastroduodenoscopy and 29 dogs had both
gastroduodenoscopy and colonoscopy.
Histopathological examination of duodenal biopsies
in the nonsurvivors revealed lymphoplasmacytic enteri-
tis (5) and mixed lymphoplasmacytic and eosinophilic
enteritis (10). In the survivor group histopathological
diagnosis based on duodenal biopsies included lympho-
plasmacytic enteritis (8) and mixed lymphoplasmacytic
and eosinophilic enteritis (18). Follow up for the sur-
vivor group ranged from 18 to 75 months (median
27 months). In the nonsurvivors group the follow up
ranged from 4 days to 24 months (median 2 months).
Outcome
Fifteen dogs died or were euthanized as a result of
CE (Tables 1 and 2). The age of the dogs at presenta-
tion which subsequently died or were euthanized
because of their CE ranged from 9 to 114 months
(median 96 months). Dogs which subsequently died had
been treated with dietary changes and antibiotics
(n = 2), dietary changes, prednisolone and antibiotics
(n = 7), and dietary changes, antibiotics, prednisolone
and other immunosuppressive medications (n = 6).
Twenty-six dogs did not die as a result of gastrointesti-
nal disease (Tables 1 and 2). Sixteen were alive at fol-
low up and 10 had died because of nongastrointestinal
diseases. The age of the dogs in the survivors group
ranged from 6 to 96 months (median 60.5 months).
Dogs in this group were treated with dietary changes
and antibiotics (n = 10), dietary changes and pred-
nisolone (n = 1), dietary changes, prednisolone and
antibiotics (n = 3) and dietary changes, prednisolone,
antibiotics and other immunosuppressive drugs (n = 1),
diet alone (n = 10), and gastroprotectants (n = 1).
Univariable analysis revealed that serum 25(OH)D,
albumin and total calcium concentrations were signiﬁ-
cantly lower in nonsurvivors compared to survivors
(Table 1, Fig 1). Age and CIBDAI scores were signiﬁ-
cantly higher in nonsurvivors compared to survivors
(Table 1). There was no signiﬁcant diﬀerence in the
number of male and female dogs between the 2 groups
(Table 1).
A binary logistic regression model was performed to
estimate the association between outcome and serum 25
(OH)D concentrations conditional on a range of other
candidate predictors. Canine inﬂammatory bowel dis-
ease activity index was not included in this model as it
has previously been shown that this measure strongly
Table 1. Univariable analysis of clinical and biochemi-
cal variables in surviving and nonsurviving dogs. The





(n = 15) P Value
Age (months) 60.5 (36–73) 96.0 (60–108) .004
Calcium mg/dL 9.68 (9.04–10.12) 8.24 (6.76–9.04) .002
Calcium mmol/L 2.42 (2.26–2.53) 2.06 (1.69–2.26)
Albumin mg/dL 3.34 (2.73–3.52) 2.45 (1.3–2.69) .0007
Albumin g/L 33.35 (27.3–35.2) 24.50 (13–26.9)
CIBDAI 6 (5–9) 10 (7–12) .0022
25(OH)D ng/mL 24.90 (15.63–39.45) 4.3 (1.6–17.0) .0003
Male/female 18/8 9/6 .73
Table 2. Impact on model akaike information criteria
(AIC) after addition of dropped predictors. An increase
in AIC represents a poorer parameter-penalized model
ﬁt.
Added Predictor AIC
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correlates with serum 25(OH)D concentrations.5 In this
analysis duodenal histology severity scores were also
included which were available for 34 of the 41 dogs.
There was no signiﬁcant diﬀerence in the histopathol-
ogy scores between dogs which died compared to the
ones which survived (P = .06). There were 10 dogs with
a score of <7, 10 dogs with a score of 7 or 8, and 14
dogs with a score of 9 or greater. The initial model
included age, sex, histopathology score as a tertile,
serum calcium, albumin, and 25(OH)D concentrations.
After stepwise AIC selection, the optimal predictive
ﬁnal model used serum 25(OH)D concentrations and
age demonstrating that vitamin D status was an inde-
pendent predictor of mortality in dogs with CE. The
odds ratio for death was 1.08 (95% conﬁdence interval
1.02–1.18) for vitamin D status and for age was 0.97
(95% conﬁdence 0.93–1.00). Table 2 shows the conse-
quences on model ﬁt following the reintroduction of
discarded predictors, demonstrating that the model
based on 25(OH)D concentrations and age was optimal.
Discussion
The main ﬁnding of this study is that serum 25(OH)
D concentrations are signiﬁcantly lower at the time of
diagnosis in dogs which died or were euthanized as a
result of a CE. This is an important ﬁnding as it is pre-
sently diﬃcult to predict outcomes in dogs with a CE.
Older age, hypoalbuminemia, and higher CIBDAI
scores are predictive of a poorer outcome in dogs with
a CE, ﬁndings which are further supported by our
research.1,23,24 This study, which demonstrates that 25
(OH)D concentration at point of diagnosis is a prog-
nostic marker in dogs with a CE, will provide addi-
tional prognostic information to owners and
veterinarians managing dogs with a CE. Further work
is needed to determine the optimal cut-oﬀ value for
vitamin D as a prognostic marker.
The mechanism(s) underlying a hypovitaminosis D
state in canine CE is unknown. Reduced dietary intake
of vitamin D in dogs with a CE maybe an important
cause of hypovitaminosis D especially as dogs do not
cutaneously produce vitamin D.25 As low vitamin D sta-
tus in dogs with a CE has been associated with a
decreased appetite5, this may, in part, explain the
reduced serum 25(OH)D concentrations that are fre-
quently observed in dogs with a CE. However, dogs with
a CE were found to have a lower 25(OH)D concentra-
tions than hospitalized ill dogs with nongastrointestinal
illnesses, many of which also have reduced appetites.5
Consequently, the inﬂuence of appetite on the vitamin D
status in dogs with a CE remains unclear.
Circulating 25(OH)D is bound to vitamin D binding
protein and albumin.26 Enteric loss of albumin is
regarded to be a signiﬁcant problem in many dogs with
a CE, notably in cases of protein losing enteropathies.27
Consequently, loss of protein-bound vitamin D into the
gastrointestinal tract could account for the low vitamin
D status in some dogs with a CE. This may explain our
earlier ﬁnding of a correlation between serum albumin
concentration and vitamin D status in dogs with a CE.5
Similarly, albumin concentrations has also been shown
to be a predictor of serum 25(OH)D concentration in
humans with IBD.28 Malabsorption might also con-
tribute to low vitamin D status in human patients with
Crohn’s disease and this could potentially inﬂuence
serum 25(OH)D concentrations in dogs with CE. How-
ever, while vitamin D absorption appears to be reduced
in patients with Crohn’s disease compared to healthy
controls, there seems to be substantial variation in
absorption of vitamin D in these patients.29 Further
studies are needed in both people and dogs with CE to
clarify the potential role of vitamin D malabsorption in
driving a hypovitaminosis D state.
Although hypovitaminosis D in CE has traditionally
been considered to be a result of intestinal disease, there
is growing evidence that hypovitaminosis D may con-
tribute to the initiation of intestinal inﬂammation. Sup-
porting evidence for a link between hypovitaminosis D
and CE comes from rodent models which have demon-
strated that vitamin D receptor knock out (VDR/)
mice are more susceptible to experimental forms of
inﬂammatory bowel disease. For example, experimen-
tally induced colitis in VDR/ mice was signiﬁcantly
more severe compared to wild-type mice.30,31 Further-
more it has also been demonstrated that supplementing
wild-type mice with vitamin D can decrease the severity
of gastrointestinal inﬂammation with chemical induced
colitis.30 In addition, it has been shown that feeding
mice a vitamin D-restricted diet can predispose to
IBD.32 A recent meta-analysis of animal and human tri-
als concluded that while many studies reported an
improvement with supplementing vitamin D, there is
insuﬃcient evidence to currently recommend vitamin D
treatment for human cases of IBD.33 Therefore, further
research is needed into the potential role of vitamin D
in the management of these diseases.
The vitamin D receptor is expressed on many
immune cell types and it is clear that vitamin D can
modulate both the innate and acquired immune
responses via eﬀects on monocytes, macrophages, den-
dritic cells, and lymphocytes.34,35 Vitamin D has also
been shown to profoundly modulate proinﬂammatory
responses.36,37 Therefore, lack of vitamin D might drive
abnormal inﬂammatory and immune processes.
Fig 1. Serum 25 hydroxyvitamin D concentrations in surviving
and nonsurviving dogs with a chronic enteropathy.
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Loss of tolerance to normally harmless bacterial and
dietary antigens is hypothesized to be important for the
development of canine CE.3 Vitamin D may also be
important in regulating the immune response to com-
mensal gut ﬂora and maintaining normal bacterial pop-
ulations. For example, dysbiosis was also reported in
VDR/ mice and Cyp27B1/ mice38 and dysbiosis
may contribute to CE in dogs.39
There is growing evidence linking vitamin D deﬁ-
ciency with disrupted intestinal mucosal barrier func-
tion. It has been proposed that altered epithelial barrier
function, resulting in increased epithelial permeability,
leads to increased exposure of the mucosal immune sys-
tem to luminal antigens and that this may contribute to
the initiation and perpetuation of chronic inﬂamma-
tion.40 This hypothesis is supported by the observation
that intestinal permeability is increased in people with
naturally occurring inﬂammatory bowel disease and
their unaﬀected relatives.41 Similar ﬁndings have been
reported in dogs with naturally occurring CE where
increased paracellular permeability has been demon-
strated by lactulose to rhamnose absorption tests.42,43
In vitro active vitamin D metabolite, 1,25-dihydroxyvi-
tamin D3 [1,25(OH)2D3], markedly enhances tight junc-
tions by increasing tight junction protein expression.44
The same study also demonstrated that VDR/ mice
were more susceptible to mucosal injury than wild-type
mice. These results suggest that vitamin D might be
important in mucosal integrity and gastrointestinal bar-
rier function which could contribute to CE.
Limitations of this study include the lack of standard-
ization in treatment regime, which is a result of the ret-
rospective nature of the study design.
In summary, this study demonstrates the serum vita-
min D concentrations are predictive of clinical outcome
in dogs with CE. Although, causality cannot be inferred
from these results, the ﬁnding that low serum 25(OH)D
concentrations are negatively correlated with outcome
highlights the need to further examine the relationship
between vitamin D homeostasis and disease develop-
ment and outcome in dogs with CE.
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